Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Raises $73.7M in IPO

NEW YORK (GenomeWeb) – Quanterix said today that it has closed its initial public offering, selling more than 4.9 million shares of common stock at $15 per share, raising $73.7 million in gross proceeds. Its shares now trade on the Nasdaq under ticker symbol QTRX.

In early afternoon trading, the company's stock was up about 5 percent at $19.08 per share.

JP Morgan Securities, Leerink Partners, and Cowen were joint book-running managers for the offering, while BTIG and Evercore Group were comanagers.

The firm previously said it would use the proceeds from its IPO to expand its commercial operations and grow its existing technology. Its plans include launching additional assays for its single-molecule technology Simoa and supporting the launch of its new instrument, Quanterix SR-X, which it launched in August.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.